Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Get Free Report) crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $16.95 and traded as low as $16.35. Pieris Pharmaceuticals shares last traded at $16.42, with a volume of 23,533 shares traded.
Analyst Upgrades and Downgrades
Separately, StockNews.com downgraded Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 16th.
Check Out Our Latest Report on PIRS
Pieris Pharmaceuticals Stock Performance
Pieris Pharmaceuticals (NASDAQ:PIRS – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($2.76) EPS for the quarter. Pieris Pharmaceuticals had a negative return on equity of 101.29% and a negative net margin of 39.71%.
Insider Buying and Selling
In other news, major shareholder Adar1 Capital Management, Llc acquired 3,000 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average cost of $15.88 per share, with a total value of $47,640.00. Following the transaction, the insider now directly owns 129,574 shares of the company’s stock, valued at $2,057,635.12. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. 8.89% of the stock is owned by corporate insiders.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
See Also
- Five stocks we like better than Pieris Pharmaceuticals
- What Investors Need to Know to Beat the Market
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- How to Choose Top Rated Stocks
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Invest in Blue Chip Stocks
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.